Bell Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$380K Buy
413
+2
+0.5% +$2.03K 0.06% 93
2025
Q4
$442K Buy
411
+75
+22% +$71.7K 0.07% 83
2025
Q3
$256K Buy
336
+13
+4% +$9.67K 0.04% 107
2025
Q2
$252K Sell
323
-5
-2% -$3.88K 0.04% 106
2025
Q1
$271K Buy
328
+13
+4% +$10.8K 0.05% 92
2024
Q4
$243K Sell
315
-9
-3% -$7.45K 0.05% 98
2024
Q3
$287K Buy
324
+2
+0.6% +$1.8K 0.05% 91
2024
Q2
$292K Buy
322
+14
+5% +$11.2K 0.06% 87
2024
Q1
$240K Buy
308
+8
+3% +$5.69K 0.05% 93
2023
Q4
$175K Buy
300
+6
+2% +$3.5K 0.04% 100
2023
Q3
$158K Buy
294
+1
+0.3% +$515 0.04% 100
2023
Q2
$137K Buy
293
+67
+30% +$28.1K 0.03% 94
2023
Q1
$77.6K Sell
226
-32
-12% -$10.8K 0.02% 124
2022
Q4
$94.4K Buy
258
+67
+35% +$23.8K 0.02% 108
2022
Q3
$62K Sell
191
-3
-2% -$951 0.02% 114
2022
Q2
$63K Buy
+194
New +$58.2K 0.02% 115
2021
Q4
$45K Buy
162
+24
+17% +$6.08K 0.01% 174
2021
Q3
$32K Buy
+138
New +$34.1K 0.01% 201

Other funds holding LLY

Bell Investment Advisors's LLY Position: Q1 2026 in Review

Bell Investment Advisors increased its Eli Lilly (LLY) stake by 0.49% in Q1 2026, buying an estimated $2.03K and bringing the position to 413 shares worth $380K. The position accounts for 0.06% of the portfolio, ranked #93.

Bell Investment Advisors first reported a position in LLY in Q3 2021 and has held it in 18 quarters since. The position peaked at $442K in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Bell Investment Advisors held 413 shares of Eli Lilly worth $380K as of Q1 2026.
  • Bell Investment Advisors bought 2 Eli Lilly shares in Q1 2026, an estimated $2.03K.
  • Eli Lilly made up 0.06% of Bell Investment Advisors's portfolio in Q1 2026, its #93 holding.
  • Bell Investment Advisors first reported a position in Eli Lilly in Q3 2021 and has held it in 18 quarters since.
  • Bell Investment Advisors's Eli Lilly position peaked at $442K in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Bell Investment Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.